Accordingly, the results should be a true reflection of the differences between the different insulins in clinical practice, and able to be generalised for the purposes of making policy decisions on provision of diabetes care, feeding economic models and reviewing the overall performance of UK care in this area. The gene discussed is INS; the disease is diabetes mellitus.